Monitor ASCO presentations (May 29 – June 2) for any positive preclinical data that could serve as a near-term catalyst. Absent data, the stock likely remains range-bound with low liquidity.
Price Chart
Executive Summary
Calidi Biotherapeutics announced that two abstracts on its RedTail platform (CLD-401 and CLD-501) were accepted for publication at the 2026 ASCO Annual Meeting. The preclinical data highlights systemic virotherapy targeting tumors and delivering IL-15 superagonist or T-cell engager payloads. The news is pre-clinical and lacks quantitative drug results, providing a low-impact catalyst ahead of the meeting.
Key Facts
- Two abstracts accepted for ASCO 2026 (May 29 – June 2, 2026) on CLD-401 and CLD-501.
- CLD-401 is a systemically delivered virotherapy expressing IL-15 superagonist.
- CLD-501 is a systemically delivered virotherapy expressing a TROP-2 T-cell engager and IL-15 SA.
- Company expects to file an IND for CLD-401 by end of 2026.
- Preclinical data only; no financial or clinical milestone achieved.
Financial Impact
No financial data disclosed; pre-revenue company with $3M market cap.
Risk Factors
- Preclinical data may not translate to clinical success; high risk of failure.
- Company needs additional capital to fund IND and trials; dilution risk.
- Low market cap and OTC listing increase volatility and liquidity risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $1.07 | awaiting T+20 | — | $0.6450 (+39.72%) |
Sep 22, 2026 4w ago | 8-K | $1.09 $0.7680 | ▲ +29.54% | ▲ +30.23% | $0.6450 (+40.83%) |
Sep 17, 2026 5w ago | 424B5 | $1.10 $0.8370 | ▲ +23.91% | ▲ +24.11% | $0.6450 (+41.36%) |
Aug 13, 2026 10w ago | 8-K | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Aug 13, 2026 10w ago | Press Release | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Jun 29, 2026 16w ago | 3 | $0.1700 $0.0933 | ▼ −45.12% | ▼ −42.80% | $0.6450 (+279.41%) |
May 26, 2026 21w ago | Press Release | $2.83 $2.51 | ▼ −11.30% | ▼ −9.24% | $0.6450 (−77.22%) |
May 22, 2026 22w ago | Press Release | $2.83 $2.51 | ▲ +11.30% | ▲ +9.24% | $0.6450 (+77.22%) |
Apr 20, 2026 27w ago | Press Release | $0.2500 $0.1830 | ▼ −26.80% | ▼ −31.00% | $0.6450 (+158.00%) |
Mar 27, 2026 30w ago | Press Release | $0.2390 $0.2240 | ▼ −6.28% | ▼ −18.87% | $0.6450 (+169.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers